Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Monday's Featured Article
A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?By Jeffrey Neal Johnson. Originally Published: 4/7/2026. 
Key Points
- Abbott's Medical Devices division continues to accelerate, demonstrating the underlying strength within the company's largest business segment.
- Abbott's impressive history of consecutive dividend increases underscores its commitment to consistently rewarding long-term shareholders.
- Strategic acquisitions are positioning Abbott to lead in new high-growth healthcare sectors, securing a powerful pipeline for future expansion.
- Special Report: Have $500? Invest in Elon’s AI Masterplan
In investing, stability is a prized commodity. Few companies embody that stability better than Abbott Laboratories (NYSE: ABT), a diversified healthcare powerhouse and a member of the Dividend Kings. For decades, investors have relied on Abbott for steady growth and dependable income. That long-standing reputation makes its recent performance particularly notable.
"How Do I Evaluate Whether An Advisor is the Right Fit For My $1M+ Portfolio?"
If you are evaluating advisors for a $1M+ portfolio, the consultation may provide more insight than marketing materials alone. Ask a pro how to assess whether an advisor's strategy may be right for you. Take this quiz to find and compare vetted financial advisors who serve your area. Take matching quiz.
Abbott Laboratories’ stock price recently hit a 52-week low, closing just above $100 in the last trading days of March. The sharp downturn has prompted many to ask whether the foundation of this industry leader is cracking. A closer look at Abbott’s situation suggests a possible disconnect between market sentiment and operational reality. The key question for long-term investors: is the market’s pessimism justified, or has a meaningful value opportunity emerged? Separating the Signal From the NoiseAbbott's decline reflects two distinct pressures. The first is an internal headwind from its Nutrition segment. Abbott’s fourth-quarter 2025 earnings report showed a 9.1% organic sales decline in this division, driven mainly by market-share losses in its U.S. pediatric business and pricing dynamics that constrained volume. Management has acknowledged the challenge and outlined a clear turnaround plan. CEO Robert B. Ford described a mix of pricing and promotional initiatives and a pipeline of at least eight new product launches in 2026 intended to reignite volume growth, with a projected return to growth in the second half of the year. The second factor is external: a broad market rotation. As economic optimism grows, investors often shift capital away from defensive sectors like the healthcare sector into higher-beta areas such as artificial intelligence (AI) and the energy sector. That rotation has pressured many fundamentally sound healthcare stocks, including Abbott, for reasons largely unrelated to their individual performance or long-term prospects. Abbott’s Engine Room Is Running StrongWhile Nutrition works through a short-term recovery, Abbott's core remains robust, led by its largest and most profitable division: Medical Devices. That segment accelerated, posting 10.4% organic growth in the most recent quarter. Abbott's diversified model helps offset the isolated weakness in Nutrition, and the company's fundamental health is most apparent in these high-performing areas.
Medical Devices: The Medical Devices business is gaining momentum, driven by innovation in critical care areas. Diabetes Care: The FreeStyle Libre franchise of continuous glucose monitors (CGM) continues to be a standout. Allowing users to track glucose without routine fingersticks, the franchise generated more than $7.5 billion in sales in 2025 and remains a major growth driver. Cardiovascular Leadership: Abbott is a leader in cardiovascular devices. Its Electrophysiology business grew at a double-digit pace, and its Structural Heart business posted 8.7% organic growth. This strength is supported by best-in-class products such as MitraClip and TriClip, which provide minimally invasive heart valve repair solutions, and a pipeline that includes the newly FDA-approved Volt PFA System for atrial fibrillation. Abbott is also pursuing strategic expansion through its acquisition of Exact Sciences. Exact Sciences is best known for Cologuard, a non-invasive colon cancer screening test, and the deal would immediately position Abbott in the growing market for cancer diagnostics. That acquisition adds a high-growth vertical that could become a meaningful revenue contributor over time. Wall Street appears cautiously optimistic. Analysts maintain a Moderate Buy consensus rating on Abbott, with an average 12-month price target of $135.47 — implying more than 30% upside from recent levels. A Bedrock of Reliability for Income InvestorsFor long-term investors focused on income, Abbott’s dividend is a standout feature. Abbott is a member of the S&P 500 Dividend Kings, an exclusive group of companies that have increased their dividend for at least 50 consecutive years. That track record reflects a strong commitment to returning capital to shareholders through market cycles. The recent drop in Abbott’s stock price has a direct benefit for new investors: a higher dividend yield. At current prices, Abbott yields about 2.5%, allowing investors to lock in a higher income rate from a historically reliable payer. The dividend payout ratio is approximately 68% of earnings, but it represents only about 37% of cash flow, indicating ample coverage and room for future increases. A Disconnect Between Price and ValueCurrent market sentiment seems out of step with Abbott's operational reality. Temporary headwinds in one division and a broad market rotation have pressured the share price, yet Abbott's core growth engines are accelerating. The Medical Devices division continues to perform strongly, the dividend remains secure, and strategic moves such as the Exact Sciences acquisition offer future catalysts. For investors with a long-term horizon, the present valuation suggests a potential gap between price and intrinsic value that merits consideration. |
